Eosinophil eotaxin receptor
    2.
    发明授权
    Eosinophil eotaxin receptor 失效
    嗜酸性粒细胞嗜酸性粒细胞趋化因子受体

    公开(公告)号:US06271347B1

    公开(公告)日:2001-08-07

    申请号:US08847296

    申请日:1997-04-24

    IPC分类号: C07K14715

    摘要: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

    摘要翻译: 已经分离,克隆和测序嗜酸性粒细胞嗜酸性粒细胞趋化因子受体。 该受体是人β-趋化因子受体,并被称为“CC CKR3”。 嗜酸性粒细胞嗜酸性粒细胞趋化因子受体可用于筛选和鉴定结合嗜酸性粒细胞嗜酸性粒细胞趋化嗜酸性粒细胞趋化因子受体的化合物。 这些化合物可用于治疗和预防特应性疾病,包括过敏性鼻炎,皮炎,结膜炎,特别是支气管哮喘。

    Assay to identify human C5a antagonists and agonists
    3.
    发明授权
    Assay to identify human C5a antagonists and agonists 失效
    测定人C5a拮抗剂和激动剂

    公开(公告)号:US5614370A

    公开(公告)日:1997-03-25

    申请号:US215137

    申请日:1994-03-18

    摘要: The invention is an assay, including a series of peptides, which allow screening for inhibitors of C5a binding targeted to the subsite on the C5a receptor occupied by the C-terminus of C5a. These peptides allow compound testing efforts to be targeted to this same subsite so that C5a agonists and antagonists can be identified. These peptides have much greater affinity (Ki

    摘要翻译: 本发明是包括一系列肽的测定法,其允许筛选靶向C5a C末端C5a受体上的亚位点的C5a结合抑制剂。 这些肽允许化合物测试努力针对同一个子站点,以便可以鉴定C5a激动剂和拮抗剂。 这些肽与C5a的天然C末端(Ki =300μM)相比具有更大的亲和力(Ki <10nM),并且已被标记以允许检测抑制这些肽在该受体亚位点处的结合的分子。 本发明可用于开发C5a的激动剂,部分激动剂和拮抗剂,本发明包括根据本发明的方法鉴定的化合物及其使用方法。